

## **Helix BioMedix Chief Scientific Officer Stepping Down, Company Focuses on Commercialization of Peptide Pipeline**

Bothell, Washington – Feb 16, 2011 – Helix BioMedix, Inc. (OTCBB:HXBM), a developer of bioactive peptides, today announced that Dr. Timothy Falla will leave his post as Vice President and Chief Scientific Officer effective February 28, 2011. Dr. Falla will assist the company on a consulting basis in managing the Helix BioMedix patent portfolio during a transitional period.

“Over the past 10 years, Tim has created and expanded our technology platform, supporting it through patent protection and advancing it to early-stage commercialization,” stated R. Stephen Beatty, the company’s President and Chief Executive Officer. “Our patent portfolio has grown to cover more than 100,000 bioactive peptides, one of the most extensive libraries in the industry. A number of these molecules are now contributing to our growing revenue base, and Helix BioMedix is intensifying its focus on the near-term commercialization of its extensive peptide and small molecule library.”

“We are pleased that Tim will continue to assist the company with matters related to existing patents and patent applications,” added Beatty. “Dr. Lijuan Zhang, who has worked alongside Tim in creating the current patent portfolio, will continue to lead our ongoing invention and discovery programs targeting the development of novel molecules. In addition, we plan to expand our R&D team with development-oriented scientists to further commercialize our existing pipeline. This reflects our belief that the company has reached an important inflection point, and the greatest stockholder value will be derived by accelerating the conversion of our substantial intellectual property into revenue-generating products for a wide range of dermal applications.”

### **About Helix BioMedix, Inc.**

Helix BioMedix, Inc. is a biopharmaceutical company with an extensive library of diverse bioactive peptides and patents covering six distinct classes and hundreds of thousands of peptide sequences. Core competencies include peptide design, synthesis and characterization together with assay development, screening, tissue culture and microbiology, leveraged through relationships with contract research organizations and peptide manufacturers. The company takes product development programs from theoretical concept to a qualified skin care active ingredient fully validated as to efficacy and safety. Applications for Helix BioMedix peptides include anti-aging cosmeceutical skin care and acne treatment as well as other topical anti-infective pharmaceuticals and wound healing applications. Striking<sup>®</sup>, Cerakine<sup>™</sup>, and SmartPeptide<sup>™</sup> are trademarks of Helix BioMedix, Inc. More information about the company and its proprietary peptides may be found on the company’s website at [www.helixbiomedix.com](http://www.helixbiomedix.com).

### **Forward Looking Statements**

This press release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding activities, events or developments that the company expects, believes or anticipates may occur in the future, including statements related to its potential growth, product development and commercialization and revenue. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the company’s ability to successfully raise additional capital, enter into revenue generating license agreements, continue its research and development efforts, including pre-clinical and clinical studies, and continue developing marketable peptide-based products, and general economic conditions. Additional assumptions, risks and uncertainties are described in detail in the company’s reports and other filings with the Securities and Exchange Commission.

Such filings are available on the company's website or at [www.sec.gov](http://www.sec.gov). Readers are cautioned that such forward-looking statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances.

**Investor Contact:**

Matt Kreps  
Shelton Group Investor Relations  
(972) 239-5119 X 125  
[mkreps@sheltongroup.com](mailto:mkreps@sheltongroup.com)

**Company Contact:**

R. Stephen Beatty  
President and CEO  
(425) 402-8400  
[sbeatty@helixbiomedix.com](mailto:sbeatty@helixbiomedix.com)